BioCentury
ARTICLE | Finance

Analyst picks & changes

November 14, 1994 8:00 AM UTC

Genzyme Corp. (GENZ)

Michael Ehrenreich of Ehrenreich & Co. initiated coverage with an "underperform," citing the company's dependence on revenues from Ceredase/Cerezyme and the uncertainty of success in the development of a family of HAL hyaluronic acid products to prevent postoperative adhesions. Those products are in Phase III trials. ...